Gene expression patterns of CRYM and SIGLEC10 in Alzheimer's disease: potential early diagnostic indicators
View abstract on PubMed
Summary
This summary is machine-generated.Researchers identified altered gene expression in Alzheimer's disease (AD) patients. Decreased crystallin mu (CRYM) and increased sialic acid-binding immunoglobulin-like lectin 10 (SIGLEC10) in blood may serve as early AD biomarkers.
Area Of Science
- Neuroscience
- Genetics
- Biomarker Discovery
Background
- Alzheimer's disease (AD) is a progressive neurological disorder leading to dementia.
- Early diagnosis of AD remains a significant challenge in clinical practice.
- Identifying reliable early diagnostic markers for AD is crucial.
Purpose Of The Study
- To investigate differential gene expression of crystallin mu (CRYM) and sialic acid-binding immunoglobulin-like lectin 10 (SIGLEC10) in Alzheimer's disease.
- To evaluate the potential of CRYM and SIGLEC10 as diagnostic biomarkers for AD.
Main Methods
- Gene expression analysis of CRYM and SIGLEC10 in whole blood samples.
- Comparison between 50 individuals diagnosed with AD and 50 healthy controls.
- Statistical analysis including correlation and receiver operating characteristic (ROC) curve analysis.
Main Results
- CRYM gene expression was significantly decreased in AD patients compared to controls.
- SIGLEC10 gene expression was significantly elevated in AD patients.
- CRYM and SIGLEC10 transcript levels showed diagnostic potential with AUCs of 0.74 and 0.81, respectively.
Conclusions
- Altered CRYM and SIGLEC10 expression patterns are potentially linked to AD pathology.
- These genes may serve as valuable biomarkers for the early detection and diagnosis of AD.
- Further validation in larger, diverse cohorts is necessary to confirm these findings and advance diagnostic strategies.

